Although some studies have suggested that GnRH agonist protocols may be associated with improved outcomes (8), prospective trials have not demonstrated significant differences in efficacy, and both protocols are currently considered equally effective in patients with endometriosis (9). The gene discussed is GNRH1; the disease is endometriosis.